Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 4;121(14):2715-24.
doi: 10.1182/blood-2012-10-461848. Epub 2013 Jan 23.

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu  1 , Zijun Y Xu-Monette, Aarthi Balasubramanyam, Ganiraju C Manyam, Carlo Visco, Alexander Tzankov, Wei-min Liu, Roberto N Miranda, Li Zhang, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L Richards, Eric D Hsi, William W L Choi, J Han van Krieken, Qin Huang, Jooryung Huh, Weiyun Ai, Maurilio Ponzoni, Andrés J M Ferreri, Xiaoying Zhao, Jane N Winter, Mingzhi Zhang, Ling Li, Michael B Møller, Miguel A Piris, Yong Li, Ronald S Go, Lin Wu, L Jeffrey Medeiros, Ken H Young
Affiliations

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu et al. Blood. .

Abstract

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Morphology and immunophenotype of CD30+ de novo DLBCL. (A-D) A case of CD30+ DLBCL of the GCB subtype (panel A, H&E; panel B, CD30; panel C, CD10; and panel D, EBER in situ hybridization). (E-H) A case of CD30+ DLBCL of the ABC subtype (panel E, H&E; panel F, CD30; panel G, CD10; and panel H, MUM1). (I-L) A case of CD30+EBV+ DLBCL (panel I, H&E; panel J, CD30; panel K, CD10; and panel L, EBER in situ hybridization). Original magnification ×1000 (A,E,I) and ×500 (all others).
Figure 2
Figure 2
Prognostic impact of CD30 expression in de novo DLBCL. (A-B) OS (A) and PFS (B) of patients with CD30+ vs CD30– DLBCL in the training set. (C) OS of patients with CD30+ vs CD30– DLBCL in the validation set. These patients were part of an independent cohort of 442 patients with available survival information (supplementary Table 1). (D) OS of patients with CD30+ vs CD30– DLBCL in combined training and validation sets.
Figure 3
Figure 3
Prognostic impact of CD30 expression in COO subtypes of DLBCL. (A-B) OS (A) and PFS (B) of patients with CD30+ DLBCL of the GCB subtype in the training set. (C) OS of patients with CD30+ DLBCL of the GCB subtype in the combined training and validation sets. (D-E) OS (D) and PFS (E) of patients with CD30+ DLBCL of the ABC subtype in the training set. (F) OS of patients with CD30+ DLBCL of the ABC subtype in the combined training and validation sets.
Figure 4
Figure 4
Gene expression profiles and GSEA analysis of CD30+ vs CD30– DLBCL. (A) Comparison of gene expression profiles between CD30+ and CD30– DLBCL. (B) GSEA for differentially expressed genes of cytokine and TNFR pathways was performed on Kyoto Encyclopedia of Genes and Genomes pathway gene sets using all the probe sets that are associated with a known gene. The gene sets with a false discovery rate q value <0.05 after performing 1000 permutations were considered to be significantly enriched.
Figure 5
Figure 5
Prognostic impact of concurrent EBV infection in CD30+ DLBCL. (A) OS of all CD30+EBER+ vs all CD30+EBER– DLBCL patients. Age range, 52 to 91 for EBV+ group; 16 to 84 for EBV– group. (B) OS of CD30+EBER+ vs CD30+EBER– DLBCL patients in >60-year-old age group. Median age, 73 for EBV+ group; 70 for EBV– group. (C) OS of CD30+EBV+ DLBCL patients in >50-year-old age group vs CD30+EBV– DLBCL in >60-year-old age group. Median age, 70 for both groups.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. pp. 233–237.
    1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. - PubMed
    1. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. - PubMed
    1. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208(5):714–723. - PubMed
    1. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109(11):4930–4935. - PubMed

Publication types

MeSH terms

Supplementary concepts